Kardigan, Inc. Common Stock

Kardigan raised $400 million in an upsized initial public offering, selling 25 million shares at $16 each and debuting on Nasdaq at $16.25 on June 18 before surging well above its IPO price in the first session. The heart-drug developer brings three late-stage cardiovascular candidates—danicamtiv, ataciguat, and tonlamarsen—and expects pivotal data in the first half of 2027, giving investors clearer milestones than the early-stage companies that flooded the market during the 2020–2021 boom. CEO Tassos Gianakakos and Chief Medical Officer Jay Edelberg previously developed mavacamten at MyoKardia, which Bristol Myers Squibb acquired for $13 billion in 2020, lending management credibility in a capital-intensive field. The offering provides runway beyond the 12 months of cash the company previously had, illustrating how biotechs are now raising funds ahead of major data readouts to avoid being caught in unfavorable markets. Analysts say the debut reflects a market that is open but selective, rewarding companies with late-stage pipelines and obvious clinical triggers rather than the broad risk appetite of the zero-rate era.

Seeking Alpha analysts weighed in on the most attractive upcoming initial public offerings following SpaceX's successful market debut. Donovan Jones highlighted Kardigan, a clinical-stage biopharma that debuted Thursday, and Bending Spoons as a potential digital media play, while noting that OpenAI and Anthropic are likely to launch soon with high demand despite challenges. Brett Ashcroft Green called SpaceX, OpenAI, and Anthropic all attractive but cautioned that retail investors face highly inflated prices after extensive private fundraising, and pointed to the Baron Partners mutual fund as a way to gain SpaceX exposure. Eugenio Catone argued that none of the upcoming AI IPOs are attractive due to unreasonable valuations, suggesting they are a strategy to cash out after a massive rally and advising retail investors not to take the bait.

Kardigan Inc. shares rose over 27% roughly one hour into their Nasdaq debut on Thursday after the heart-health focused biotech raised $400 million in its initial public offering. The company sold 25 million shares at $16 each, above the previously marketed range of 23.3 million shares at $14 to $16 apiece. Shares opened at $16.25 and were trading above $20.30 by approximately 1:30 p.m. in New York, giving the company a market value of nearly $1.8 billion. Kardigan is developing drugs for genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, and reported a net loss of $56.1 million in the first quarter of 2026. The offering was led by JPMorgan Chase, Jefferies Financial Group, Leerink Partners, and Toronto-Dominion Bank, and the shares trade under the symbol KARD.